|
1
|
Mirabello L, Troisi RJ and Savage SA:
Osteosarcoma incidence and survival rates from 1973 to 2004: Data
from the Surveillance, Epidemiology, and End Results Program.
Cancer. 115:1531–1543. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ottaviani G and Jaffe N: The epidemiology
of osteosarcoma. Cancer Treat Res. 152:3–13. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Picci P: Osteosarcoma (osteogenic
sarcoma). Orphanet J Rare Dis. 2:62007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Powers M, Zhang W, Lopez-Terrada D,
Czerniak BA and Lazar AJ: The molecular pathology of sarcomas.
Cancer Biomark. 9:475–491. 2010.PubMed/NCBI
|
|
5
|
Bovée JV and Hogendoorn PC: Molecular
pathology of sarcomas: Concepts and clinical implications. Virchows
Arch. 456:193–199. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
de Álava E: Molecular pathology in
sarcomas. Clin Transl Oncol. 9:130–144. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Osuna D and de Alava E: Molecular
pathology of sarcomas. Rev Recent Clin Trials. 4:12–26. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Berger M, Muraro M, Fagioli F and Ferrari
S: Osteosarcoma derived from donor stem cells carrying the Norrie's
disease gene. N Engl J Med. 359:2502–2504. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
He M, Wang Z, Zhao J, Chen Y and Wu Y:
COL1A1 polymorphism is associated with risks of osteosarcoma
susceptibility and death. Tumour Biol. 35:1297–1305. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
He ML, Wu Y, Zhao JM, Wang Z and Chen YB:
PIK3CA and AKT gene polymorphisms in susceptibility to osteosarcoma
in a Chinese population. Asian Pac J Cancer Prev. 14:5117–5122.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jia J, Tian Q, Liu Y, Shao ZW and Yang SH:
Interactive effect of bisphenol A (BPA) exposure with −22G/C
polymorphism in LOX gene on the risk of osteosarcoma. Asian Pac J
Cancer Prev. 14:3805–3808. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhang SL, Mao NF, Sun JY, Shi ZC, Wang B
and Sun YJ: Predictive potential of glutathione S-transferase
polymorphisms for prognosis of osteosarcoma patients on
chemotherapy. Asian Pac J Cancer Prev. 13:2705–2709. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang W, Wang J, Song H, Liu J, Song B and
Cao X: Cytotoxic T-lymphocyte antigen-4 +49G/A polymorphism is
associated with increased risk of osteosarcoma. Genet Test Mol
Biomarkers. 15:503–506. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Patard JJ, Pouessel D, Bensalah K and
Culine S: Targeted therapy in renal cell carcinoma. World J Urol.
26:135–140. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Motzer RJ, Hutson TE, Tomczak P,
Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik
C, Kim ST, et al: Sunitinib versus interferon alfa in metastatic
renal-cell carcinoma. N Engl J Med. 356:115–124. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Watson CJ, Webb NJ, Bottomley MJ and
Brenchley PE: Identification of polymorphisms within the vascular
endothelial growth factor (VEGF) gene: Correlation with variation
in VEGF protein production. Cytokine. 12:1232–1235. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jain L, Vargo CA, Danesi R, Sissung TM,
Price DK, Venzon D, Venitz J and Figg WD: The role of vascular
endothelial growth factor SNPs as predictive and prognostic markers
for major solid tumors. Mol Cancer Ther. 8:2496–2508. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yan Y, Liang H, Li T, Guo S, Li M, Li S
and Qin X: Vascular endothelial growth factor +936C/T polymorphism
and breast cancer risk: A meta-analysis of 13 case-control studies.
Tumour Biol. 35:2687–2692. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Martinez-Fierro ML, Garza-Veloz I,
Rojas-Martinez A, Ortiz-Lopez R, Castruita-de la Rosa C,
Ortiz-Castro Y, Lazalde-Ramos BP, Cervantes-Villagrana AR,
Castañeda-Lopez ME, Gomez-Guerra L, et al: Positive association
between vascular endothelial growth factor (VEGF) −2578 C/A variant
and prostate cancer. Cancer Biomark. 13:235–241. 2013.PubMed/NCBI
|
|
20
|
Zhang Y, Li S, Xiao HQ, Hu ZX, Xu YC and
Huang Q: Vascular endothelial growth factor gene polymorphisms and
renal cell carcinoma: A systematic review and meta-analysis. Oncol
Lett. 6:1068–1078. 2013.PubMed/NCBI
|
|
21
|
Wang Z, Wen P, Luo X, Fang X, Wang Q, Ma F
and Lv J: Association of the vascular endothelial growth factor
(VEGF) gene single-nucleotide polymorphisms with osteosarcoma
susceptibility in a Chinese population. Tumour Biol. 35:3605–3610.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tie Z, Bai R, Zhai Z, Zhang G, Zhang H,
Zhao Z, Zhou D and Liu W: Single nucleotide polymorphisms in VEGF
gene are associated with an increased risk of osteosarcoma. Int J
Clin Exp Pathol. 7:8143–8149. 2014.PubMed/NCBI
|
|
23
|
Enneking WF, Spanier SS and Goodman MA: A
system for the surgical staging of musculoskeletal sarcoma. Clin
Orthop Relat Res. 106–120. 1980.PubMed/NCBI
|
|
24
|
Salven P, Teerenhovi L and Joensuu H: A
high pretreatment serum vascular endothelial growth factor
concentration is associated with poor outcome in non-Hodgkin's
lymphoma. Blood. 90:3167–3172. 1997.PubMed/NCBI
|
|
25
|
Leng WD, He MN, Chen QL, Gong H, Zhang L
and Zeng XT: Vascular endothelial growth factor (VEGF) gene
polymorphisms and risk of head and neck cancer: A meta-analysis
involving 2,444 individuals. Mol Biol Rep. 40:5987–5992. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kushner EJ and Bautch VL: Building blood
vessels in development and disease. Curr Opin Hematol. 20:231–236.
2013.PubMed/NCBI
|
|
27
|
Roy H, Bhardwaj S and Ylä-Herttuala S:
Biology of vascular endothelial growth factors. FEBS Lett.
580:2879–2887. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Renner W, Kotschan S, Hoffmann C,
Obermayer-Pietsch B and Pilger E: A common 936 C/T mutation in the
gene for vascular endothelial growth factor is associated with
vascular endothelial growth factor plasma levels. J Vasc Res.
37:443–448. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Koukourakis MI, Papazoglou D,
Giatromanolaki A, Bougioukas G, Maltezos E and Sivridis E: VEGF
gene sequence variation defines VEGF gene expression status and
angiogenic activity in non-small cell lung cancer. Lung Cancer.
46:293–298. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Liu H, Wang S and Huang C: VEGFA+936C/T
and −634G/C polymorphisms and gastric cancer risk: A meta-analysis.
Asian Pac J Cancer Prev. 12:1979–1983. 2011.PubMed/NCBI
|
|
31
|
Zhao Z, Ba C, Wang W, Wang X, Xue R and Wu
X: Vascular endothelial growth factor (VEGF) gene polymorphisms and
colorectal cancer: A meta-analysis of epidemiologic studies. Genet
Test Mol Biomarkers. 16:1390–1394. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Deng ZC, Cao C, Yu YM, Ma HY and Ye M:
Vascular endothelial growth factor −634G/C and vascular endothelial
growth factor −2578C/A polymorphisms and lung cancer risk: A
case-control study and meta-analysis. Tumour Biol. 35:1805–1811.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yao W, Yan R, Ma L, Wan H, Yu Y, Cheng X
and Li Y: Vascular endothelial growth factor gene polymorphism
(−634G/C) and breast cancer risk. Tumour Biol. 35:7793–7798. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Sa-Nguanraksa D, Chuangsuwanich T,
Pongpruttipan T, Kummalue T, Rojananin S, Ratanawichhitrasin A,
Prasarttong-Osoth P, Chuthatisith S, Pisarnturakit P,
Aeumrithaicharoenchok W, et al: Vascular endothelial growth factor
634G/C polymorphism is associated with increased breast cancer risk
and aggressiveness. Mol Med Rep. 8:1242–1250. 2013.PubMed/NCBI
|
|
35
|
Liao WC, Lin JT, Wu CY, Huang SP, Lin MT,
Wu AS, Huang YJ and Wu MS: Serum interleukin-6 level but not
genotype predicts survival after resection in stages II and III
gastric carcinoma. Clin Cancer Res. 14:428–434. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Sfar S, Saad H, Mosbah F and Chouchane L:
Combined effects of the angiogenic genes polymorphisms on prostate
cancer susceptibility and aggressiveness. Mol Biol Rep. 36:37–45.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Hefler LA, Mustea A, Könsgen D, Concin N,
et al: Vascular endothelial growth factor gene polymorphisms are
associated with prognosis in ovarian cancer. Clin Cancer Res.
13:898–901. 2007. View Article : Google Scholar : PubMed/NCBI
|
